查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1986641

CAR-T细胞疗法市场规模、份额和趋势分析报告：按产品、疾病、应用、地区和细分市场预测（2026-2033年）

CAR T-cell Therapy Market Size, Share & Trends Analysis Report By Product (Abecma, Breyanzi, Carvykti, Kymriah), By Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

CAR-T细胞疗法市场概述

全球 CAR-T 细胞疗法市场预计到 2025 年将价值 58.2 亿美元，预计到 2033 年将达到 223.6 亿美元。

预计从 2026 年到 2033 年，该市场将以 18.06% 的复合年增长率成长。推动市场成长的因素包括癌症患者数量的增加、个人化细胞疗法的普及、基因编辑技术的进步以及支持性法规。

癌症负担加重

癌症，尤其是白血病、淋巴瘤和多发性骨髓瘤等血液癌症的日益流行，正在推动CAR-T细胞疗法产业的发展。传统治疗方法往往难以实现长期缓解，而CAR-T细胞疗法透过改造患者自身的T细胞使其靶向癌细胞，从而提供更高的疗效和更持久的疗效。全球癌症发生率的不断攀升，进一步刺激了对这些先进的个人化治疗方法的需求。

进行性或难治性血液肿瘤治疗选择有限，推动了CAR-T细胞疗法市场的成长。这些治疗方法满足了亟待解决的关键医疗需求，医护人员和病患对其认知度的提升也促进了其应用。随着临床试验扩展到其他类型的癌症和固态肿瘤，预计需求将进一步成长，CAR-T细胞疗法将成为肿瘤学的核心研究方向。

目录

第一章：调查方法和范围

第二章执行摘要

第三章 市场变数、趋势与范围

  • 市场历史及展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
  • 产业分析工具
    • 波特五力分析
    • PESTEL 分析

第四章 产品业务分析

  • CAR-T细胞疗法市场：产品波动分析
  • Abekuma（Idekabutadiene Vicrucel）
    • Abekuma（Idekabutadiene Viclecel）市场，2021-2033
  • Braiang（溶卡他二烯马拉色尔）
    • Breyange（Lysocabtadiene Malarocell）市场，2021-2033
  • Calvicti（Siltacaptadiene autoleucel）
    • Calvikti（Siltacaptadiene Autoleucel）市场，2021-2033
  • Kymriah (Tisagenrekresel)
    • Kymriah（Tisagenrekresel）市场，2021-2033
  • Tekartus (Brexcabutagene autreucer)
    • Tekartas（Brexcabutagene autoleucel）市场，2021-2033
  • Yeskarta（Akshikabutagene Sirolsel）
    • Yeskarta（Axiskabutagene Siroluesel）市场，2021-2033
  • 其他的
    • 其他市场，2021-2033年

第五章：依疾病指征进行业务分析

  • CAR-T细胞疗法市场：疾病特异性波动分析
  • 白血病
    • 白血病市场，2021-2033年
  • 淋巴瘤
    • 淋巴瘤市场，2021-2033年
  • 多发性骨髓瘤
    • 多发性骨髓瘤市场，2021-2033年
  • 其他的
    • 其他市场，2021-2033年

第六章 依最终用途进行业务分析

  • CAR-T细胞疗法市场：终端用户波动分析
  • 医院
    • 医院市场，2021-2033年
  • 癌症治疗中心
    • 癌症治疗中心市场，2021-2033年

第七章 区域业务分析

  • 2025 年和 2033 年 CAR-T 细胞疗法的区域市场份额
  • 北美洲
    • 2021-2033年北美CAR-T细胞疗法市场
    • 我们
    • 加拿大
  • 欧洲
    • 2021-2033年欧洲CAR-T细胞疗法市场
    • 英国
    • 德国
  • 亚太地区
    • 2021-2033年亚太地区CAR-T细胞疗法市场
    • 日本
    • 中国
  • 世界其他地区
    • 2021-2033年世界其他地区CAR-T细胞疗法市场

第八章 竞争情势

  • 公司分类
  • 策略蓝图
  • Company Position Analysis, 2025
  • 公司简介/列表
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Gilead Sciences, Inc.
    • Johnson &Johnson Services, Inc.
    • JW Therapeutics（Shanghai）Co., Ltd.
    • bluebird bio, Inc.
    • Merck &Co., Inc.
    • Sangamo Therapeutics
    • Sorrento Therapeutics, Inc.
    • GSK plc.
Product Code: GVR-4-68040-090-4

CAR T-cell Therapy Market Summary

The global CAR T-cell therapy market size was estimated at USD 5.82 billion in 2025 and is projected to reach USD 22.36 billion by 2033, growing at a CAGR of 18.06% from 2026 to 2033. Market growth is driven by rising cancer prevalence, adoption of personalized cell therapies, advances in gene editing, and supportive regulations.

Rising Cancer Burden

The rising prevalence of cancer, especially blood cancers like leukemia, lymphoma, and multiple myeloma, is driving the CAR T-cell therapy industry. Traditional treatments often fail to achieve long-term remission, while CAR T-cell therapies, which engineer a patient's T-cells to target cancer, offer higher efficacy and durable responses. Increasing global cancer incidence is boosting demand for these advanced, personalized treatments.

Limited options for aggressive or treatment-resistant blood cancers support CAR T-cell market growth. These therapies address critical unmet needs, and rising awareness among healthcare professionals and patients is driving adoption. Expanding clinical trials into other cancers and solid tumors is expected to increase demand further, making CAR T-cell therapy a central focus in oncology.

Global CAR T-cell Therapy Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global CAR T-cell therapy market report based on product, disease indication, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Abecma (idecabtagene vicleucel)
  • Breyanzi (lisocabtagene maraleucel)
  • Carvykti (ciltacabtagene autoleucel)
  • Kymriah (tisagenlecleucel)
  • Tecartus (brexucabtagene autoleucel)
  • Yescarta (axicabtagene ciloleucel)
  • Others
  • Disease Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Cancer Treatment Centers
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
  • Asia Pacific
    • Japan
    • China
  • Rest of World

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Segment
      • 1.1.1.2. Disease Indication Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objective
    • 1.4.1. Objective 1
    • 1.4.2. Objective2
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis:
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising cancer burden
      • 3.2.1.2. Personalized treatment advantage
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory complexity
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis

Chapter 4. Product Business Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. CAR T-cell Therapy Market: Product Movement Analysis
  • 4.3. Abecma (idecabtagene vicleucel)
    • 4.3.1. Abecma (idecabtagene vicleucel) market, 2021 - 2033 (USD Million)
  • 4.4. Breyanzi (lisocabtagene maraleucel)
    • 4.4.1. Breyanzi (lisocabtagene maraleucel) market, 2021 - 2033 (USD Million)
  • 4.5. Carvykti (ciltacabtagene autoleucel)
    • 4.5.1. Carvykti (ciltacabtagene autoleucel) market, 2021 - 2033 (USD Million)
  • 4.6. Kymriah (tisagenlecleucel)
    • 4.6.1. Kymriah (tisagenlecleucel) market, 2021 - 2033 (USD Million)
  • 4.7. Tecartus (brexucabtagene autoleucel)
    • 4.7.1. Tecartus (brexucabtagene autoleucel) market, 2021 - 2033 (USD Million)
  • 4.8. Yescarta (axicabtagene ciloleucel)
    • 4.8.1. Yescarta (axicabtagene ciloleucel) market, 2021 - 2033 (USD Million)
  • 4.9. Others
    • 4.9.1. Others market, 2021 - 2033 (USD Million)

Chapter 5. Disease Indication Business Analysis

  • 5.1. Disease Indication Segment Dashboard
  • 5.2. CAR T-cell Therapy Market: Disease Indication Movement Analysis
  • 5.3. Leukemia
    • 5.3.1. Leukemia market, 2021 - 2033 (USD Million)
  • 5.4. Lymphoma
    • 5.4.1. Lymphoma market, 2021 - 2033 (USD Million)
  • 5.5. Multiple Myeloma
    • 5.5.1. Multiple myeloma market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others market, 2021 - 2033 (USD Million)

Chapter 6. End Use Business Analysis

  • 6.1. End Use Segment Dashboard
  • 6.2. CAR T-cell Therapy Market: End Use Movement Analysis
  • 6.3. Hospitals
    • 6.3.1. Hospitals market, 2021 - 2033 (USD Million)
  • 6.4. Cancer treatment centers
    • 6.4.1. Cancer treatment centers market, 2021 - 2033 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. CAR T-cell Therapy Market Share By Region, 2025 & 2033
  • 7.2. North America
    • 7.2.1. North America CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Competitive Scenario
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. U.S. CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Competitive Scenario
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Canada CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. UK CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Germany CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Japan CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. China CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  • 7.5. Rest of World
    • 7.5.1. Rest of World CAR T-cell Therapy Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Position Analysis, 2025
  • 8.4. Company Profiles/Listing
    • 8.4.1. Bristol-Myers Squibb Company
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Novartis AG
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Gilead Sciences, Inc.
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Johnson & Johnson Services, Inc.
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. JW Therapeutics (Shanghai) Co., Ltd.
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. bluebird bio, Inc.
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Merck & Co., Inc.
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Sangamo Therapeutics
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Sorrento Therapeutics, Inc.
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. GSK plc.
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives

List of Tables

  • Table 1. Global CAR T-cell therapy market, by region, 2021 - 2033 (USD Million)
  • Table 2. Global CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 3. Global CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 4. Global CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 5. North America CAR T-cell therapy market, by country, 2021 - 2033 (USD Million)
  • Table 6. North America CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 7. North America CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 8. North America CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 9. U.S. CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 10. U.S. CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 11. U.S. CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 12. Canada CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 13. Canada CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 14. Canada CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 15. Europe CAR T-cell therapy market, by country, 2021 - 2033 (USD Million)
  • Table 16. Europe CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 17. Europe CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 18. Europe CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 19. UK CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 20. UK CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 21. UK CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 22. Germany CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 23. Germany CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 24. Germany CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 25. Asia Pacific CAR T-cell therapy market, by country, 2021 - 2033 (USD Million)
  • Table 26. Asia Pacific CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 27. Asia Pacific CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 28. Asia Pacific CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 29. Japan CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 30. Japan CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 31. Japan CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 32. China CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 33. China CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 34. China CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 35. Rest or World CAR T-cell therapy market, by country, 2021 - 2033 (USD Million)
  • Table 36. Rest of World CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 37. Rest of World CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 38. Rest of World CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 CAR T-cell therapy market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Market trends & outlook
  • Fig. 16 PESTEL analysis
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 CAR T-cell therapy market: Product outlook & key takeaways
  • Fig. 19 CAR T-cell therapy market: Product movement analysis
  • Fig. 20 Global abecma (idecabtagene vicleucel) market, 2021 - 2033 (USD Million)
  • Fig. 21 Global breyanzi (lisocabtagene maraleucel) market, 2021 - 2033 (USD Million)
  • Fig. 22 Global carvykti (ciltacabtagene autoleucel) market, 2021 - 2033 (USD Million)
  • Fig. 23 Global kymriah (tisagenlecleucel) market, 2021 - 2033 (USD Million)
  • Fig. 24 Global tecartus (brexucabtagene autoleucel) market, 2021 - 2033 (USD Million)
  • Fig. 25 Global yescarta (axicabtagene ciloleucel) market, 2021 - 2033 (USD Million)
  • Fig. 26 Global others market, 2021 - 2033 (USD Million)
  • Fig. 27 CAR T-cell therapy market: Disease Indication outlook key takeaways
  • Fig. 28 CAR T-cell therapy market: Disease Indication movement analysis
  • Fig. 29 Global leukemia market, 2021 - 2033 (USD Million)
  • Fig. 30 Global lymphoma market, 2021 - 2033 (USD Million)
  • Fig. 31 Global multiple myeloma market, 2021 - 2033 (USD Million)
  • Fig. 32 Global others market, 2021 - 2033 (USD Million)
  • Fig. 33 CAR T-cell therapy market: End Use outlook key takeaways
  • Fig. 34 CAR T-cell therapy market: End Use movement analysis
  • Fig. 35 Global hospitals market, 2021 - 2033 (USD Million)
  • Fig. 36 Global cancer treatment centers market, 2021 - 2033 (USD Million)
  • Fig. 37 Regional outlook
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 North America CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 US CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Canada CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Europe CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Germany CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 UK CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Asia Pacific CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Japan CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 China CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Rest of World CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)